As an engineer, I never look at a glass galf full or half empty. I look at the issue of the glass being oversized. The last PR is reflecting as usual the systemic problem with ENZC : the front end AI and research (cost center) being oversized and overpriductive for the back end operations (profit center some day). So how do we solve the issue?
Downsize the AI (short term impact but stupid imo)
Spin it off allowing it to work for third parties as a swing factor, and potentially turn it into a orofit center. No shirt term impact though since getting agreements in place will take a long time, based on their perfirmance on NDAs
Beef up back end internally (medium term, huge need for non existing cash, but retaining full profits longer terms)
Or work DILIGENTLY on these supposed NDAs and partnerships so that they start generating revenues as IPF immune sales are likely to be modest, we would have heard by now if the product was a blockbuster, we will know soon if/when the 10K gets out. In any case They need to hire somebody to run the back end. Dr Chandra does not have the profile for priduction, field operations, supply chain, QC, sales,… he must focus on his core scientific competences. Until we actually get ONE product on the launch pad, this is dead money, as it has been fir the last two years because of broken 2021 promises for milestones. Credibility and walking the talk is key at this point. 5 weeks to go until the « monumental shift » deadline… you would guess having a range of 6 to 12 months was wide enough. So there must be a roadblock somewhere